DE69210229D1 - Dihydrochinolin NMDA Antagonisten - Google Patents

Dihydrochinolin NMDA Antagonisten

Info

Publication number
DE69210229D1
DE69210229D1 DE69210229T DE69210229T DE69210229D1 DE 69210229 D1 DE69210229 D1 DE 69210229D1 DE 69210229 T DE69210229 T DE 69210229T DE 69210229 T DE69210229 T DE 69210229T DE 69210229 D1 DE69210229 D1 DE 69210229D1
Authority
DE
Germany
Prior art keywords
dihydroquinoline
nmda antagonists
nmda
antagonists
sulfanimide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69210229T
Other languages
English (en)
Other versions
DE69210229T2 (de
Inventor
Boyd Harrison
Bruce Baron
David Stemerick
Ian Mcdonald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69210229D1 publication Critical patent/DE69210229D1/de
Publication of DE69210229T2 publication Critical patent/DE69210229T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69210229T 1991-02-27 1992-02-11 Dihydrochinolin NMDA Antagonisten Expired - Lifetime DE69210229T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66178091A 1991-02-27 1991-02-27
US70000491A 1991-05-14 1991-05-14
PCT/US1992/001093 WO1992015565A1 (en) 1991-02-27 1992-02-11 Nmda antagonists

Publications (2)

Publication Number Publication Date
DE69210229D1 true DE69210229D1 (de) 1996-05-30
DE69210229T2 DE69210229T2 (de) 1996-11-14

Family

ID=27098383

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69210229T Expired - Lifetime DE69210229T2 (de) 1991-02-27 1992-02-11 Dihydrochinolin NMDA Antagonisten

Country Status (14)

Country Link
EP (1) EP0573562B1 (de)
JP (1) JP3465794B2 (de)
KR (1) KR100224045B1 (de)
AT (1) ATE137225T1 (de)
AU (1) AU660969B2 (de)
CA (1) CA2104297C (de)
DE (1) DE69210229T2 (de)
DK (1) DK0573562T3 (de)
ES (1) ES2089511T3 (de)
FI (1) FI103202B (de)
GR (1) GR3019772T3 (de)
HU (1) HU217425B (de)
NO (1) NO180485C (de)
WO (1) WO1992015565A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
DK0731792T3 (da) * 1993-11-29 1999-09-13 Merrell Pharma Inc Heterocycliske benzensulfonyliminderivater som inhibitorer af IL-1-virkning
US5684017A (en) * 1993-11-29 1997-11-04 Merrell Pharmaceuticals Inc. Benzenesulfonylimine derivatives as inhibitors of IL-1 action
IN2012DN06631A (de) 2010-02-16 2015-10-23 Pfizer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
EP0386839B1 (de) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
AU626418B2 (en) * 1989-05-16 1992-07-30 Merrell Pharmaceuticals Inc. Excitatory amino acid antagonists

Also Published As

Publication number Publication date
EP0573562A1 (de) 1993-12-15
GR3019772T3 (en) 1996-07-31
HUT67301A (en) 1995-03-28
KR100224045B1 (ko) 1999-10-15
JPH06505746A (ja) 1994-06-30
AU1532092A (en) 1992-10-06
NO933042D0 (no) 1993-08-26
EP0573562B1 (de) 1996-04-24
NO180485B (no) 1997-01-20
NO933042L (no) 1993-08-26
CA2104297A1 (en) 1992-08-28
WO1992015565A1 (en) 1992-09-17
AU660969B2 (en) 1995-07-13
HU217425B (hu) 2000-01-28
FI103202B1 (fi) 1999-05-14
FI933762A0 (fi) 1993-08-26
ES2089511T3 (es) 1996-10-01
FI933762A (fi) 1993-08-26
HU9302433D0 (en) 1993-11-29
DE69210229T2 (de) 1996-11-14
NO180485C (no) 1997-04-30
ATE137225T1 (de) 1996-05-15
FI103202B (fi) 1999-05-14
JP3465794B2 (ja) 2003-11-10
KR930703257A (ko) 1993-11-29
CA2104297C (en) 2003-05-27
DK0573562T3 (da) 1996-05-13

Similar Documents

Publication Publication Date Title
NO914300D0 (no) Fremgangsmaate for fremstilling av 3-amidoindolderivater
FI945434A (fi) 4-markatpoasetyyliamino/2/bentsatsepinoni (3) johdannaisia ja niiden käyttö enkefalinaasi-inhibiittoreina
NO930035D0 (no) Eksitatoriske aminosyreantagonister
ES2072607T3 (es) Derivados 3 indolil tioacetato.
DE69230224D1 (de) Potenzierung von nmda-antagonisten
DE69210229D1 (de) Dihydrochinolin NMDA Antagonisten
DK0532629T3 (da) 1-Piperidinyl-alkanoylarylsulfonamid-derivater
DK0457324T3 (da) Heterocycliske NMDA antagonister

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS INC. (N.D.GES.D. STAATES PENNSYLVANIA), GR

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US